Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.

Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated, “After discussing our pharmaceutical products and initiatives with the FDA, Cannabis Science has taken certain steps to meet this potentially urgent situation. Although there is much yet to be done, I am very optimistic that we have an opportunity to have our products available to help meet this challenge.”

Dr. Melamede concludes with an outline of Cannabis Science corporate guidance on its FDA procedures: “There are a number of critical capabilities that must be assembled into a cohesive whole. The guiding principle of both our scientific and business operations is that, by using appropriate independent contractors that are experts in their fields, the whole is greater than the sum of its parts.

Most importantly, we want everyone to understand the efficient and effective corporate structure that we are creating with holistic principles in mind. We are assembling teams in all the necessary arenas required for our growth and success. We have an agreement with a successful organic producer to provide us with the raw material. We are establishing a genetic testing facility to insure the production of consistent botanical products, as required for FDA approval, using state of the art procedures. We have identified a CGMP compliant processor who will make an FDA approvable extract for further processing by another qualified and experienced manufacturer, who will produce the final commercial product after FDA approval.

Our compliance team of professionals will oversee all of these activities with their many years of FDA experience. We are extremely pleased with the history and quality of expertise of the team that we are bringing together to face the immediate urgent challenges. We again thank our investors for their confidence in providing us with the necessary resources for this revolutionary undertaking. We have a number of exciting new initiatives we plan to announce shortly and we feel honored to be commissioned to make this happen."


Cannabis Science Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
UCLA receives seven grants totaling $6.4 million for cannabis research